Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.39 |
| ▸ | RARB | P10826 | 2/20 | 0.37 |
| ▸ | RARA | P10276 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.35 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | WDR5 | P61964 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19722588 | 0.90 | S1PR1 (0.42) | FFAR4S1PR1S1PR3RARBFFAR1 | |
| SCHEMBL21321790 | 0.89 | FFAR4 (0.43) | FFAR4S1PR1S1PR3RARBRARA | |
| SCHEMBL19722391 | 0.87 | S1PR1 (0.37) | FFAR4S1PR1S1PR3RARBRARA | |
| SCHEMBL19722403 | 0.87 | S1PR1 (0.39) | FFAR4S1PR1S1PR3RARBRARA | |
| SCHEMBL21322014 | 0.87 | RARB (0.38) | FFAR4S1PR1S1PR3RARBRARA | |
| SCHEMBL19722392 | 0.86 | S1PR1 (0.37) | FFAR4S1PR1S1PR3RARBRARA | |
| SCHEMBL19721922 | 0.85 | RARB (0.43) | FFAR4S1PR1S1PR3RARBRARA | |
| SCHEMBL19722090 | 0.85 | S1PR1 (0.47) | FFAR4S1PR1S1PR3RARBRARA | |
| SCHEMBL19722298 | 0.84 | S1PR1 (0.37) | FFAR4S1PR1S1PR3RARBRARA | |
| SCHEMBL19721896 | 0.84 | RARB (0.43) | FFAR4RARBRARAFFAR1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214615-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT | JNC CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| US-10392339-B2 | Polymerizable polar compound, liquid crystal composition, and liquid crystal display element | JNC CORPORATION (JP) | 2019-08-27 | — | — | US | disclosed |
| US-20170369418-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORPORATION (JP) | 2017-12-28 | — | — | US | disclosed |
| EP-3257839-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2017-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392339-B2 | Polymerizable polar compound, liquid crystal composition, and liquid crystal display element | SP1, HVCN1, CXCR1 | FFAR4 2665/4885S1PR1 106/4885S1PR3 122/4885 |
| US-20170369418-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | SP1, SPIN1, SAV1 | FFAR4 2555/4885S1PR1 122/4885S1PR3 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.